{"0EH.F": {"short_name": "TOLERANZIA AB", "long_name": "Toleranzia AB", "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "10B.MU": {"short_name": "BIOSERVO TECHNOLAB", "long_name": "Bioservo Technologies AB (publ)", "summary": "Bioservo Technologies AB (publ) develops wearable muscle strengthening systems worldwide. It offers Ironhand, a robotic muscle strengthening system for professional applications; and Carbonhand, a grip enhancing device that facilitates a normal movement pattern for use in healthcare applications. The company was founded in 2006 and is based in Kista, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "MUN", "market": "dr_market", "country": "Sweden", "city": "Kista"}, "16E.F": {"short_name": "EPISURF MEDICAL AB B", "long_name": "Episurf Medical AB (publ)", "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, and the United Kingdom. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for treating elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Epiguide MOS, a surgical drill guide, which is designed for use in mosaicplasty surgery for treatment of cartilage and deep underlying bone defects in the knee joint. In addition, the company offers \u00c2\u00b5iFidelity system for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was founded in 2008 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "1AD1.F": {"short_name": "ADDLIFE AB B", "long_name": "AddLife AB (publ)", "summary": "AddLife AB (publ), together with its subsidiaries, supplies equipment, instruments, and reagents to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries in Sweden, Finland, Denmark, Norway, and internationally. The company operates through two segments, Labtech and Medtech. The Labtech segment provides analysis instruments, equipment, microscopes, consumables and reagents, as well as software support and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare markets. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "1DO.F": {"short_name": "DOXA AB (PUBL)", "long_name": "Doxa AB (publ)", "summary": "Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "1XT.F": {"short_name": "XINTELA AB", "long_name": "Xintela AB (publ)", "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "27R.F": {"short_name": "RAYSEARCH LABS B  SK 0,40", "long_name": "RaySearch Laboratories AB (publ)", "summary": "RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, a oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, and data handling and machine learning. In addition, it provides training courses, as well as customer support services. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "2B4.F": {"short_name": "BONESUPPORT HOLDING AB", "long_name": "Bonesupport Holding AB (publ)", "summary": "Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden, rest of Europe, North America, and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its also developing preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company's products are used in orthopedic markets. The company was founded in 1999 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "2BQ.F": {"short_name": "GHP SPECIALTY CARE AB SK1", "long_name": "GHP Specialty Care AB (publ)", "summary": "GHP Specialty Care AB (publ) provides healthcare services in the Nordic region and internationally. The company operates specialist clinics that offer services in various areas, including orthopaedics, spine surgery/spine care, obesity surgery and diabetes care, gastroenterology, urology, general surgery, arrhythmia, sports medicine, neurology, skin, and specialist dentistry. It operates 22 specialty care clinics in the Nordic Region. The company was formerly known as Global Health Partner AB (publ) and changed its name to GHP Specialty Care AB (publ) in May 2015. GHP Specialty Care AB (publ) was founded in 2006 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "2I9.F": {"short_name": "KAROLINSKA DEVELOP.AB", "long_name": "Karolinska Development AB (publ)", "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "3EE.F": {"short_name": "KANCERA AB", "long_name": "Kancera AB (publ)", "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "3F8.F": {"short_name": "Q-LINEA AB", "long_name": "Q-linea AB (publ)", "summary": "Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system for sepsis patients. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was founded in 2008 and is headquartered in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "3KT.F": {"short_name": "KONTIGO CARE  AB", "long_name": "Kontigo Care AB (publ)", "summary": "Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Alcohol, a digital medical device for the drug rehabilitation; and Previct Gambling, a digital tool for the treatment and prevention of work at the gaming addiction. Kontigo Care AB (publ) was founded in 2013 and is based in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "49Z.F": {"short_name": "CELLINK AB AK B  O.N.", "long_name": "Cellink AB (publ)", "summary": "Cellink AB (publ) designs and develops bioprinting technologies that enable researchers to 3D print organs and tissue for applications primarily in pharmaceutical to cosmetic industries worldwide. It offers bioprinters, imaging systems, dispensing solutions, and bioinks in the field of academic and clinical medicine for labs and scientists worldwide. The company's bioprinting solutions include BIO X, a bioprinter for life-science companies, researchers, and innovators; BIO X6, a bioprinting platform for printing complex structures; INKREDIBLE and INKREDIBLE+, which are bioprinting solutions for skin, cartilage tissue, and others; Holograph X, a solution that leverages high-resolution holographic stereolithography to bioprint small structures; Lumen X, a solution that offers applications in microfluidics, cell-laden hydrogels, macroporous structures, and others; and tool heads and print heads. It also offers biofluidics solutions, which include I-DOT, a solution for liquid-handling tasks; single-cell printer, an automated laboratory instrument; c.sight, a single-cell dispensing technology for cell line development and single-cell genomics; b.sight, a solution that enables prokaryotic cell isolation in the sub-micron range; and f.sight, a solution that dispenses unlabeled and fluorescent cells. The company offers bioinks for various applications, such as drug screening, tissue models, tissue regeneration, organoids, immunotherapy, microfluidics, scaffolds, encapsulation, wound healing, cosmetics, educational models, and others; CELLCYTE X, a live cell microscopy imaging system; and accessories, such as consumables, needles, and nozzles. Its customers also include universities, hospitals, and public and commercial laboratories. Cellink AB (publ) has a collaboration with MedImmune; and strategic partnership with Made In Space, Inc. It also offers products online. The company was founded in 2016 and is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "4CX.F": {"short_name": "CYXONE AB  SK-,75", "long_name": "Cyxone AB (publ)", "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "4K4.F": {"short_name": "STAYBLE THERAPEUTICS AB", "long_name": "Stayble Therapeutics AB (publ)", "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "4Z7.F": {"short_name": "IRRAS AB", "long_name": "IRRAS AB (publ)", "summary": "IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to improve the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. The company also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include SynergyDuo Ventricular Catheter (H610), and Parenchymal Catheter (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. The company markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "52Q.F": {"short_name": "AEGIRBIO AB", "long_name": "AegirBio AB (publ)", "summary": "Aegirbio AB, a diagnostic company, offers tests to monitor and optimize the dosage of biological drugs in Sweden. The company focuses on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology, and neurology space. It offers moNATor, a first dose-monitoring laboratory test to multiple sclerosis for healthcare professionals and patients. The company is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "52X.F": {"short_name": "MAGLE CHEMOSWED HOLDING", "long_name": "Magle Chemoswed Holding AB (publ)", "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "5GV.F": {"short_name": "GENOVIS AB  SE-,40", "long_name": "Genovis AB (publ.)", "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "5IU.F": {"short_name": "ISOFOL MEDICAL AB", "long_name": "Isofol Medical AB (publ)", "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "5J2.F": {"short_name": "GABATHER AB (PUBL) SK-,44", "long_name": "Gabather AB (publ)", "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "5J3.F": {"short_name": "SCIBASE HOLDING AB", "long_name": "SciBase Holding AB (publ)", "summary": "SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions.in Europe and internationally. The company offers Nevisense, a point-of-care detection device for non-visual detection of malignant melanoma. It serves public hospitals and private dermatology clinics. The company has a collaboration agreement with Swiss Institute of Allergy and Asthma Research. The company was founded in 1998 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "5J6.F": {"short_name": "OSSDSIGN AB", "long_name": "OssDsign AB (publ)", "summary": "OssDsign AB (publ), a medtech company, designs, manufactures, and markets implants for healing of bone defects in Sweden and internationally. Its products include OSSDSIGN cranial, an implant solution for cranioplasty patients, as well as related accessories; OSSDSIGN facial to treat patients with complex facial skeletal defects; and OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage. The company was founded in 2011 and is headquartered in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "5J9.F": {"short_name": "FLUICELL AB", "long_name": "Fluicell AB (publ)", "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "5JE.F": {"short_name": "BACTIGUARD HLDG B", "long_name": "Bactiguard Holding AB (publ)", "summary": "Bactiguard Holding AB (publ), a medical device company, engages in the research and development, production, marketing, and sale of infection prevention solutions primarily in Sweden and Malaysia. Its infection prevention solutions prevent healthcare associated infections caused by medical devices. The company's products portfolio reduces the risk of infections in the urinary tract, the blood stream, and the respiratory tract areas. Its product portfolio consists of indwelling Foley catheters that are used for drainage and irrigation of the bladder or for the collection and measurement of patient urine; endotracheal tubes for use in airway management by oral or nasal intubation of the trachea; and central venous catheters, which is used to administer drugs and intravenous solutions, sample blood, and for blood pressure monitoring. The company markets its products through distributors in 40 countries. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Tullinge"}, "5LU.F": {"short_name": "SIMRIS ALG AB  B", "long_name": "Simris Alg AB (publ)", "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Hammenh\u00c3\u00b6g"}, "61LA.F": {"short_name": "SECTRA AB B(P.S.)SK 0,125", "long_name": "Sectra AB (publ)", "summary": "Sectra AB (publ) provides IT systems for managing medical images and patient information related to diagnostic imaging. The company's Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; maintenance services in the form of support and system monitoring; and consulting services related to integration, system design, data migration, and business development. Its Secure Communications segment develops and sells products and services for secure voice and data communications, and protection of society's sensitive IT infrastructure; customized encryption systems and products; and critical infrastructure, which offers security and threat analyses and system monitoring services for control systems in society's critical operations. The company's Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; and products for medical education and research projects. It serves public and private healthcare providers comprising hospitals, and hospital and private clinic chains; and government agencies and defense departments. Sectra AB (publ) sells its products through its sales organizations and distribution partners in Africa, Europe, the Middle East, North America, Oceania, Southeast Asia, and Japan. The company was founded in 1978 and is headquartered in Link\u00c3\u00b6ping, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Link\u00c3\u00b6ping"}, "65G.F": {"short_name": "NEXTCELL PHARMA AB", "long_name": "NextCell Pharma AB", "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "6FN.F": {"short_name": "KLARIA PHARMA HOLDING AB", "long_name": "Klaria Pharma Holding AB (publ.)", "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "6MA.F": {"short_name": "AMBEA AB O.N.", "long_name": "Ambea AB (publ)", "summary": "Ambea AB (publ) provides residential care services for people with special needs in Sweden and Norway. The company operates through five segments: Vardaga, Nytida, Stendi, Altiden, and Klara. It offers permanent residential placements, short-term placements, relief care, and short-break care services; home care services, including cleaning, washing, shopping, personal nursing, cooking, walks, and companionship; and support services, such as homes for care or residence, assisted living facilities, supportive living facilities, family homes, sheltered housing, non-residential care, and needs assessments for children, young people and adults, as well as day-care centers, elementary schools, special needs elementary schools, and special needs upper secondary schools. The company also provides residential and care services for adults with disabilities, abuse problems, early-onset dementia, psychiatric problems, and mental illnesses, as well as disability care services for adults and children; accommodation in family homes and assisted living facilities for children and young people with various problems, which include self-harming behaviour, criminality, and substance abuse; short-break residential facilities for children and young people with disabilities; and user-controlled personal assistance services. In addition, it offers senior apartments, nursing homes, home care facilities, and rehabilitation services; and ambulatory nurses. Further, the company supplies temporary doctors, nurses, psychologists, and speech pathologists. Ambea AB (publ) was founded in 1996 and is headquartered in Solna, Sweden. Ambea AB (publ) is subsidiary of Actor S.C.A.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "6XP.SG": {"short_name": "XSpray Pharma AB Namn-Aktier o.", "long_name": "Xspray Pharma AB (publ)", "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "6Y4.F": {"short_name": "VICORE PHARMA HOLDING AB", "long_name": "Vicore Pharma Holding AB (publ)", "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "78D.F": {"short_name": "ALZINOVA AB", "long_name": "Alzinova AB", "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "7AC.F": {"short_name": "ACARIX AB", "long_name": "Acarix AB (publ)", "summary": "Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases. The company offers CADScor System for the diagnosis of coronary artery disease. It operates in Germany, Sweden, Denmark, and internationally. Acarix AB (publ) was founded in 2009 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "7AL.F": {"short_name": "ALLIGATOR BIOSC. AB O.N.", "long_name": "Alligator Bioscience AB (publ)", "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "7AT.F": {"short_name": "ATTENDO AB", "long_name": "Attendo AB (publ)", "summary": "Attendo AB (publ) provides financed care services in Sweden, Finland, Norway, and Denmark. The company offers care services for older people in nursing homes and home care. It also provides care services for people with disabilities; people with disabilities; social psychiatry; homes for children with special needs; consultant supported family home care services; crisis and acute accommodations; substance abuse care services; and care homes for people with neuropsychiatric conditions. In addition, the company offers home care services based on outsourcing contracts. Attendo AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Danderyd"}, "7CA.F": {"short_name": "CAMURUS AB", "long_name": "Camurus AB (publ)", "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "7D2.F": {"short_name": "SEDANA MEDICAL AB", "long_name": "Sedana Medical AB (publ)", "summary": "Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides isoflurane/sevoflurane and Sevorane QuickFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. In addition, the company develops IsoConDa, a therapy for inhalation sedation in intensive care. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Danderyd"}, "7PL.F": {"short_name": "PROSTALUND AB", "long_name": "ProstaLund AB (publ)", "summary": "ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "7V3.F": {"short_name": "CANTARGIA AB", "long_name": "Cantargia AB (publ)", "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "80R.F": {"short_name": "AROCELL AB", "long_name": "AroCell AB (publ)", "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "99B.F": {"short_name": "QUIAPEG PHARMAC.H.SK-1,20", "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)", "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "9IB.SG": {"short_name": "Infant Bacterial Therapeutics N", "long_name": "Infant Bacterial Therapeutics AB (publ)", "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "A39.F": {"short_name": "ARJO AB B", "long_name": "Arjo AB (publ)", "summary": "Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, prevention of pressure ulcers, prevention of deep vein thrombosis, and for obstetric and cardiac diagnostics. It also provides services, such as training in connection with product sales. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmo, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Distribution", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "A6X.F": {"short_name": "AXICHEM AB A", "long_name": "aXichem AB", "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ABLI.ST": {"short_name": "Abliva AB", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "AC6.F": {"short_name": "ALZECURE PHARMA AB", "long_name": "AlzeCure Pharma AB (publ)", "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "ACARIX.ST": {"short_name": "Acarix AB", "long_name": "Acarix AB (publ)", "summary": "Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases. The company offers CADScor System for the diagnosis of coronary artery disease. It operates in Germany, Sweden, Denmark, and internationally. Acarix AB (publ) was founded in 2009 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ACE.ST": {"short_name": "Ascelia Pharma AB", "long_name": "Ascelia Pharma AB (publ)", "summary": "Ascelia Pharma AB (publ) operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase III for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase II for the treatment of gastric cancer. The company was founded in 2000 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ACOU.ST": {"short_name": "AcouSort AB", "long_name": "AcouSort AB (publ)", "summary": "AcouSort AB (publ), a biotech company, develops proprietary bioanalytical and clinical applications based on acoustophoresis. It offers AcouTrap, a tabletop research platform for acoustic trapping; AcouPlasma, a blood-plasma separation module that enables analysis of blood plasma from whole blood samples; and AcouWash, a stand-alone table top research tool, which applies acoustic forces to focus cells. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "ADDERA.ST": {"short_name": "AdderaCare AB", "long_name": "AdderaCare AB", "summary": "AdderaCare AB, through its subsidiaries, operates in the home care sector. The company offers ramps for housing adaptations; stairs and lifts, and bathroom equipment for people with functional limitations; mobility aids for people with special needs; sensory stimulation aids; sensory rooms; sensory furniture; vestibular products; motor training products; orthopaedic shoes; orthoses; and prosthesis and components for prosthesis. It also provides construction brackets; products for gross and fine motor functions; orthotics; orthopaedic aids; three-wheel bikes; supervised cycling bikes; mobility scooters; and wheelchair scooters. The company primarily serves municipalities, county councils, and private individuals. The company was formerly known as Mastaban AB and changed its name to AdderaCare AB in 2016. AdderaCare AB was founded in 2013 and is based in Helsingborg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Helsingborg"}, "ADDLF": {"short_name": "ADDLIFE AB", "long_name": "AddLife AB (publ)", "summary": "AddLife AB (publ), together with its subsidiaries, supplies equipment, instruments, and reagents to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries in Sweden, Finland, Denmark, Norway, and internationally. The company operates through two segments, Labtech and Medtech. The Labtech segment provides analysis instruments, equipment, microscopes, consumables and reagents, as well as software support and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare markets. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "ADDV-A.ST": {"short_name": "ADDvise Group AB A", "long_name": "ADDvise Group AB (publ)", "summary": "ADDvise Group AB (publ), through its subsidiaries, develops and supplies equipment and services to healthcare and research facilities in private and public sectors in Sweden and internationally. The company's Lab business unit offers laboratory furnishings, safety ventilation products, climate rooms, clean rooms, and laboratory apparatus. Its Healthcare business unit provides medical devices and consumable materials, including defibrillators and chairs for use in the urology and gynecology areas, as well as surgical tables for medical care. The company was formerly known as ADDvise Lab Solutions AB (publ) and changed its name to ADDvise Group AB (publ) in September 2015. ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ADDV-B.ST": {"short_name": "ADDvise Group AB B", "long_name": "ADDvise Group AB (publ)", "summary": "ADDvise Group AB (publ), through its subsidiaries, develops and supplies equipment and services to healthcare and research facilities in private and public sectors in Sweden and internationally. The company's Lab business unit offers laboratory furnishings, safety ventilation products, climate rooms, clean rooms, and laboratory apparatus. Its Healthcare business unit provides medical devices and consumable materials, including defibrillators and chairs for use in the urology and gynecology areas, as well as surgical tables for medical care. The company was formerly known as ADDvise Lab Solutions AB (publ) and changed its name to ADDvise Group AB (publ) in September 2015. ADDvise Group AB (publ) was founded in 1989 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "AEGIR.ST": {"short_name": "AegirBio AB", "long_name": "AegirBio AB (publ)", "summary": "Aegirbio AB, a diagnostic company, offers tests to monitor and optimize the dosage of biological drugs in Sweden. The company focuses on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology, and neurology space. It offers moNATor, a first dose-monitoring laboratory test to multiple sclerosis for healthcare professionals and patients. The company is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "AINO.ST": {"short_name": "Aino Health AB", "long_name": "Aino Health AB (publ)", "summary": "Aino Health AB (publ) provides corporate health management solutions for private and public organizations in Finland. It offers HealthManager, a software as a service; SafetyManager platform that combines critical safety management data and processes; HealthDesk, a multichannel service, which an employee could contact immediately after feeling sick or unable to work to receive the required professional help; and TeleHealth services. The company also provides health management business process outsourcing; and consulting services. Aino Health AB (publ) is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ALIF-B.ST": {"short_name": "AddLife AB ser. B", "long_name": "AddLife AB (publ)", "summary": "AddLife AB (publ), together with its subsidiaries, supplies equipment, instruments, and reagents to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries in Sweden, Finland, Denmark, Norway, and internationally. The company operates through two segments, Labtech and Medtech. The Labtech segment provides analysis instruments, equipment, microscopes, consumables and reagents, as well as software support and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, and home healthcare markets. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ALLPF": {"short_name": "AROCELL AB", "long_name": "AroCell AB (publ)", "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Uppsala"}, "ALZ.ST": {"short_name": "Alzinova AB", "long_name": "Alzinova AB", "summary": "Alzinova AB, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of Alzheimer's disease in Sweden. It focuses on developing ALZ-101, an oligomer-directed vaccine; and ALZ-201, a monoclonal antibody that is used for the treatment of oligomeric A\u00c3\u009f. The company was founded in 2011 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "ALZCUR.ST": {"short_name": "AlzeCure Pharma AB", "long_name": "AlzeCure Pharma AB (publ)", "summary": "AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of diseases and conditions that affect the central nervous system. The company is developing five drug candidates based on the NeuroRestore and Alzstatin research platforms. Its pipeline drug candidates include ACD855, which is in Phase I clinical trial for sleep disruptions, traumatic brain injuries, and Alzheimer's disease; ACD856, ACD679, and ACD680 for Alzheimer's disease; ACD857 for eye/ear indications; VR1 that is in Phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "AMBEA.ST": {"short_name": "Ambea AB", "long_name": "Ambea AB (publ)", "summary": "Ambea AB (publ) provides residential care services for people with special needs in Sweden and Norway. The company operates through five segments: Vardaga, Nytida, Stendi, Altiden, and Klara. It offers permanent residential placements, short-term placements, relief care, and short-break care services; home care services, including cleaning, washing, shopping, personal nursing, cooking, walks, and companionship; and support services, such as homes for care or residence, assisted living facilities, supportive living facilities, family homes, sheltered housing, non-residential care, and needs assessments for children, young people and adults, as well as day-care centers, elementary schools, special needs elementary schools, and special needs upper secondary schools. The company also provides residential and care services for adults with disabilities, abuse problems, early-onset dementia, psychiatric problems, and mental illnesses, as well as disability care services for adults and children; accommodation in family homes and assisted living facilities for children and young people with various problems, which include self-harming behaviour, criminality, and substance abuse; short-break residential facilities for children and young people with disabilities; and user-controlled personal assistance services. In addition, it offers senior apartments, nursing homes, home care facilities, and rehabilitation services; and ambulatory nurses. Further, the company supplies temporary doctors, nurses, psychologists, and speech pathologists. Ambea AB (publ) was founded in 1996 and is headquartered in Solna, Sweden. Ambea AB (publ) is subsidiary of Actor S.C.A.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "ANNX.ST": {"short_name": "Annexin Pharmaceuticals AB", "long_name": "Annexin Pharmaceuticals AB (publ)", "summary": "Annexin Pharmaceuticals AB (publ), a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ARCOMA.ST": {"short_name": "Arcoma AB", "long_name": "Arcoma AB", "summary": "Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in V\u00c3\u00a4xj\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "V\u00c3\u00a4xj\u00c3\u00b6"}, "ARJO-B.ST": {"short_name": "Arjo AB ser. B", "long_name": "Arjo AB (publ)", "summary": "Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, prevention of pressure ulcers, prevention of deep vein thrombosis, and for obstetric and cardiac diagnostics. It also provides services, such as training in connection with product sales. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmo, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Distribution", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "AROC.ST": {"short_name": "AroCell AB (publ)", "long_name": "AroCell AB (publ)", "summary": "AroCell AB (publ), a vitro diagnostics company, focuses on the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company offers TK 210 ELISA, a kit for the determination of Thymidine Kinase 1 in human blood. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was founded in 2003 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "ARRJF": {"short_name": "ARJO AB", "long_name": "Arjo AB (publ)", "summary": "Arjo AB (publ) develops and sells medical devices and solutions for patients with reduced mobility and age-related health challenges in North America, Western Europe, and internationally. The company offers products and solutions for patient handling, hygiene, disinfection, medical beds, prevention of pressure ulcers, prevention of deep vein thrombosis, and for obstetric and cardiac diagnostics. It also provides services, such as training in connection with product sales. The company serves private and public institutions that provide acute and long-term care. Arjo AB (publ) was founded in 1957 and is headquartered in Malmo, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Distribution", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "ASAP.ST": {"short_name": "Asarina Pharma AB", "long_name": "Asarina Pharma AB (publ)", "summary": "Asarina Pharma AB (publ) researches and develops pharmaceutical products. Its flagship product is Sepranolone that is in Phase IIb clinical trial to treat premenstrual dysphoric disorder and menstrual migraine. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016. Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "ATORX.ST": {"short_name": "Alligator Bioscience AB", "long_name": "Alligator Bioscience AB (publ)", "summary": "Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific antibody formats for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB (CD137) in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody to treat solid tumors and hematologic cancers. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "ATT.ST": {"short_name": "Attendo AB", "long_name": "Attendo AB (publ)", "summary": "Attendo AB (publ) provides financed care services in Sweden, Finland, Norway, and Denmark. The company offers care services for older people in nursing homes and home care. It also provides care services for people with disabilities; people with disabilities; social psychiatry; homes for children with special needs; consultant supported family home care services; crisis and acute accommodations; substance abuse care services; and care homes for people with neuropsychiatric conditions. In addition, the company offers home care services based on outsourcing contracts. Attendo AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Danderyd"}, "AXIC-A.ST": {"short_name": "aXichem AB ser. A", "long_name": "aXichem AB", "summary": "aXichem AB develops, patents, and markets natural-analogue industrial compounds for the marine, pest control, feed ingredient, and medical application markets in Sweden and internationally. It offers aXiphen-repellent, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; aXiphen-feed ingredient for pig and poultry diets; and aXiphen for use in various foods and dietary supplements, as well as in the pharmaceutical industry. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "B6E.F": {"short_name": "SWEDISH ORPHAN BIOVIT.SK1", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Solna"}, "B9A.F": {"short_name": "BIOARCTIC AB B", "long_name": "BioArctic AB (publ)", "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "BACTI-B.ST": {"short_name": "Bactiguard Holding AB ser. B", "long_name": "Bactiguard Holding AB (publ)", "summary": "Bactiguard Holding AB (publ), a medical device company, engages in the research and development, production, marketing, and sale of infection prevention solutions primarily in Sweden and Malaysia. Its infection prevention solutions prevent healthcare associated infections caused by medical devices. The company's products portfolio reduces the risk of infections in the urinary tract, the blood stream, and the respiratory tract areas. Its product portfolio consists of indwelling Foley catheters that are used for drainage and irrigation of the bladder or for the collection and measurement of patient urine; endotracheal tubes for use in airway management by oral or nasal intubation of the trachea; and central venous catheters, which is used to administer drugs and intravenous solutions, sample blood, and for blood pressure monitoring. The company markets its products through distributors in 40 countries. Bactiguard Holding AB (publ) was founded in 2005 and is headquartered in Tullinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Tullinge"}, "BGAIF": {"short_name": "BIOGAIA AG", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "BINV.ST": {"short_name": "BioInvent International AB", "long_name": "BioInvent International AB (publ)", "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "BIOA-B.ST": {"short_name": "BioArctic AB ser. B", "long_name": "BioArctic AB (publ)", "summary": "BioArctic AB (publ), a research intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disease in Sweden. Its products include BAN2401, a humanized monoclonal antibody, which is in Phase 3 clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia/traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical phase for patients with early Alzheimer's disease. The company also develops BAN0805, an anti-alpha-synuclein antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase 1/2 clinical trial for spinal cord injuries. In addition, it develops imaging and biochemical biomarkers that are in preclinical phase for treating Alzheimer's disease; imaging and biochemical biomarkers for Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier. The company has collaborations with Eisai and AbbVie; a research collaboration with Brain Biomarker Solutions in Gothenburg AB to develop diagnostics for Alzheimer's disease; and a research collaboration agreement with University of Oslo. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "BIOG-B.ST": {"short_name": "BioGaia AB ser. B", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "BIOGY": {"short_name": "BIOGAIA AG", "long_name": "BioGaia AB (publ)", "summary": "BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates in Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of baby and child care, including infantile colic, infections, functional abdominal pain, diarrhea, functional constipation, and regurgitation; gut health comprising diarrhoea and constipation; gastrointestinal health consisting of Helicobacter pylori\u00c2\u0096the gastric ulcer bacterium; and oral health, including gingivitis and periodontitis, caries, and halitosis. The company offers its products under the brand name of BioGaia through pharmacies and retail outlets. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "BIOS.ST": {"short_name": "Bioservo Technologies AB", "long_name": "Bioservo Technologies AB (publ)", "summary": "Bioservo Technologies AB (publ) develops wearable muscle strengthening systems worldwide. It offers Ironhand, a robotic muscle strengthening system for professional applications; and Carbonhand, a grip enhancing device that facilitates a normal movement pattern for use in healthcare applications. The company was founded in 2006 and is based in Kista, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Kista"}, "BIOT.ST": {"short_name": "Biotage AB", "long_name": "Biotage AB", "summary": "Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "BIOVF": {"short_name": "SWEDISH ORPHAN BIOVITRUM AB", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Solna"}, "BIOVIC-B.ST": {"short_name": "Biovica International AB ser. B", "long_name": "Biovica International AB (publ)", "summary": "Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring of cancer therapies and predict patient outcome in Europe, the United States, and Asia. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves pharmaceutical companies and contract research organizations. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "BIOWKS.ST": {"short_name": "Bio-Works Technologies AB", "long_name": "Bio-Works Technologies AB (publ)", "summary": "Bio-Works Technologies AB (publ) researches, develops, manufactures, and supplies agarose based resins used to separate proteins and other biomolecules. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography (IMAC) resins; ion exchange resins; OptioBio glass columns; and size exclusion chromatography (SEC) resins. The company's products are used in antibody, His-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines purification process. Bio-Works Technologies AB (publ) founded in 2006 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "BIX0.F": {"short_name": "BIOINVENT INTERN.  SK 2", "long_name": "BioInvent International AB (publ)", "summary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "BOEUF": {"short_name": "BONESUPPORT HOLDING AB", "long_name": "Bonesupport Holding AB (publ)", "summary": "Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden, rest of Europe, North America, and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its also developing preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company's products are used in orthopedic markets. The company was founded in 1999 and is headquartered in Lund, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Lund"}, "BONEX.ST": {"short_name": "BONESUPPORT HOLDING AB", "long_name": "Bonesupport Holding AB (publ)", "summary": "Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Sweden, rest of Europe, North America, and internationally. The company offers CERAMENT Bone Void Filler used to fill gaps and voids in bone; CERAMENT G, a gentamicin-eluting injectable synthetic bone substitute; and CERAMENT V, a vancomycin-eluting synthetic bone substitute. Its also developing preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company's products are used in orthopedic markets. The company was founded in 1999 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "BOUL.ST": {"short_name": "Boule Diagnostics AB", "long_name": "Boule Diagnostics AB (publ)", "summary": "Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. It provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning kits and plastic micro capillaries under the Swelab, Medonic, and Quintus brands; and veterinary clinical chemistry analyzer and diagnostics systems under the Exigo brand. The company sells its products directly in Sweden and the United States, as well as through distributors internationally. It serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and companies in blood diagnostics. The company has operations in Sweden, the United States, Mexico, and Russia. Boule Diagnostics AB (publ) was founded in 1956 and is headquartered in Sp\u00c3\u00a5nga, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Sp\u00c3\u00a5nga"}, "BTPC.F": {"short_name": "ACTIVE BIOTECH  SK 10", "long_name": "Active Biotech AB (publ)", "summary": "Active Biotech AB (publ), a biotechnology company, together with its subsidiaries, develops pharmaceuticals for the treatment of cancer and inflammatory diseases in Sweden. The company is involved in developing Naptumomab, an immunotherapy that is in Phase Ib/II clinical trial for treatment of solid tumors; and Tasquinimod, an immunomodulator to treat multiple myeloma. It is also developing Laquinimod, an immunomodulator or the treatment of eye disorders; wet age-related macular degeneration and uveitis; and Crohn's disease, an inflammatory bowels disease. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab. Active Biotech AB (publ) was incorporated in 1982 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "C26.F": {"short_name": "CELLAVISION AB  SK -,15", "long_name": "CellaVision AB (publ)", "summary": "CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers reagents, analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. The company also provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. In addition, it offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. Further, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, the cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "C5G.F": {"short_name": "OREXO AB  SK-,40", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "CALT": {"short_name": "Calliditas Therapeutics AB", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "NMS", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "CALTX.ST": {"short_name": "Calliditas Therapeutics AB", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "CAMX.ST": {"short_name": "Camurus AB", "long_name": "Camurus AB (publ)", "summary": "Camurus AB (publ), a pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Europe, North America, and Asia. It offers Buvidal, an injection solution for the treatment of opioid dependence; and episil oral liquid is a medical device for the treatment of inflammatory and painful conditions in the oral cavity. The company's products pipeline also includes CAM2038 that is in phase III clinical trials for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment acromegaly and in phase II clinical trials for the treatment neuroendocrine tumors; and CAM2043 that is in Phase II clinical trials for treatment of pulmonary arterial hypertension. In addition, it develops CAM2032 for the treatment of prostate cancer; CAM4071, which has completed Phase I clinical trials for the treatment of Endocrine disorder; CAM4072 that is in phase III clinical trials for the treatment of rare genetic obesity disorders; and CAM4083, a pre-clinical stage product for treatment of myasthenia gravis, immune-mediated necrotizing myopathy, and other tissue disorders, as well as CAM2047, CAM2048, and CAM2058 for the treatment of chemotherapy induced nausea and vomiting, postoperative pain, and postoperative nausea and vomiting. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CANTA.ST": {"short_name": "Cantargia AB", "long_name": "Cantargia AB (publ)", "summary": "Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CEVI.ST": {"short_name": "CellaVision AB", "long_name": "CellaVision AB (publ)", "summary": "CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers reagents, analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. The company also provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. In addition, it offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. Further, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, the cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CLBIO.ST": {"short_name": "Corline Biomedical AB", "long_name": "Corline Biomedical AB", "summary": "Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "CLNK-B.ST": {"short_name": "CELLINK AB ser. B", "long_name": "Cellink AB (publ)", "summary": "Cellink AB (publ) designs and develops bioprinting technologies that enable researchers to 3D print organs and tissue for applications primarily in pharmaceutical to cosmetic industries worldwide. It offers bioprinters, imaging systems, dispensing solutions, and bioinks in the field of academic and clinical medicine for labs and scientists worldwide. The company's bioprinting solutions include BIO X, a bioprinter for life-science companies, researchers, and innovators; BIO X6, a bioprinting platform for printing complex structures; INKREDIBLE and INKREDIBLE+, which are bioprinting solutions for skin, cartilage tissue, and others; Holograph X, a solution that leverages high-resolution holographic stereolithography to bioprint small structures; Lumen X, a solution that offers applications in microfluidics, cell-laden hydrogels, macroporous structures, and others; and tool heads and print heads. It also offers biofluidics solutions, which include I-DOT, a solution for liquid-handling tasks; single-cell printer, an automated laboratory instrument; c.sight, a single-cell dispensing technology for cell line development and single-cell genomics; b.sight, a solution that enables prokaryotic cell isolation in the sub-micron range; and f.sight, a solution that dispenses unlabeled and fluorescent cells. The company offers bioinks for various applications, such as drug screening, tissue models, tissue regeneration, organoids, immunotherapy, microfluidics, scaffolds, encapsulation, wound healing, cosmetics, educational models, and others; CELLCYTE X, a live cell microscopy imaging system; and accessories, such as consumables, needles, and nozzles. Its customers also include universities, hospitals, and public and commercial laboratories. Cellink AB (publ) has a collaboration with MedImmune; and strategic partnership with Made In Space, Inc. It also offers products online. The company was founded in 2016 and is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "CLS-B.ST": {"short_name": "Clinical Laserthermia Systems A", "long_name": "Clinical Laserthermia Systems AB (publ)", "summary": "Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden. The company offers TRANBERG, a cancer immunotherapy system that includes a laser unit with unique monitoring capabilities and tailored single-use products primarily developed for imILT treatment; and applicator kit. It also is developing products for the treatment of breast, pancreatic, skin, and prostate cancers, as well as other solid cancer tumors. Clinical Laserthermia Systems AB (publ) has a collaboration agreement with Image Guided Therapy SA to develop and commercialize a software product for MR-generated temperature monitoring; collaborative license and co-development agreement with MRI Interventions, Inc. to provide navigation and laser ablation platforms for use in spine and neurosurgery; and clinical trial collaboration with Toronto General Hospital regarding MRI-guided laser ablation treatment of prostate cancer. The company is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CMOTEC-B.ST": {"short_name": "Scandinavian ChemoTech AB B", "long_name": "Scandinavian ChemoTech AB (publ)", "summary": "Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. The company markets its products through distribution channels and a network of opinion leaders in South East Asia, India, and the Philippines. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "CONTX.OL": {"short_name": "CONTEXTVISION AB", "long_name": "ContextVision AB (publ)", "summary": "ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. It operates through two segments, Medical Imaging and Digital Pathology. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include US PLUSView, an image enhancement software product for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; GOPiCE, a technology for volumetric image enhancement in real-time; and REALiCE, a volumetric image enhancement and rendering solution for visualization. The company also provides Altumira/Altumira Plus, a solution for various digital radiography systems; GOPView XR2Plus for x-ray systems for human and veterinary examinations; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; GOPView Mammo3, an image enhancement software for screening and diagnostic mammography; and INIFY Prostate, an AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.", "currency": "NOK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "OSL", "market": "no_market", "country": "Sweden", "city": "Stockholm"}, "CRAD-B.ST": {"short_name": "C-RAD AB ser. B", "long_name": "C-Rad AB (publ)", "summary": "C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, an advanced solution for particle therapy; Cyrpa laser positioning products; and Gemini, an X-ray detector optimized for electronic portal imaging device in radiation therapy. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "CUR.ST": {"short_name": "Curando Nordic AB", "long_name": "Curando Nordic AB (publ)", "summary": "Curando Nordic AB (publ) provides personal care and health services using digital technology in Sweden. It offers services for work environment, as well as solutions for businesses, such as work checklist, E-learning-work environment bas, and education in ergonomics. The company has a strategic cooperation with the Arena Group for services in the areas of health and rehabilitation, crew and recruitment, and career and conversion. The company was formerly known as Rethinking Care Sweden AB (publ) and changed its name to Curando Nordic AB (publ) in June 2018. Curando Nordic AB (publ) was founded in 2016 and is based in Sollentuna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Sollentuna"}, "CYXO.ST": {"short_name": "Cyxone AB", "long_name": "Cyxone AB (publ)", "summary": "Cyxone AB (publ), a clinical biotech company, develops immunomodulatory drugs for the treatment of autoimmune diseases. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and T20K that would enter clinical Phase I for multiple sclerosis. The company was founded in 2015 and is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "DIGN.ST": {"short_name": "Dignitana AB", "long_name": "Dignitana AB (publ.)", "summary": "Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. It offers DigniCap, a scalp cooling system used to reduce hair loss from certain chemotherapy treatments, as well as in the treatment of breast cancer. Dignitana AB (publ.) was incorporated in 2007 is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "DIZTF": {"short_name": "DIGNITANA AB", "long_name": "Dignitana AB (publ.)", "summary": "Dignitana AB (publ.), a medical technology company, develops, produces, and markets medical cooling devices primarily in the United States. It offers DigniCap, a scalp cooling system used to reduce hair loss from certain chemotherapy treatments, as well as in the treatment of breast cancer. Dignitana AB (publ.) was incorporated in 2007 is headquartered in Lund, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Lund"}, "DMN.F": {"short_name": "DIAMYD MEDICAL B", "long_name": "Diamyd Medical AB (publ)", "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "DMYD-B.ST": {"short_name": "Diamyd Medical AB ser. B", "long_name": "Diamyd Medical AB (publ)", "summary": "Diamyd Medical AB (publ) engages in developing therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunomodulating diabetes vaccine for the treatment of type 1 diabetes and latent autoimmune diabetes, which is in Phase IIb clinical development; and Remygen, an oral regenerative and immunomodulatory drug candidate for the treatment of autoimmune and type 2 diabetes, which is in Phase I/II clinical development. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "DOXA.ST": {"short_name": "Doxa AB", "long_name": "Doxa AB (publ)", "summary": "Doxa AB (publ), a dental company, develops, manufactures, and commercializes bioceramic dental products under the Ceramir brand worldwide. It offers Crown & Bridge, a dental cement that is used for permanent cementing of crowns and bridges. The company was founded in 1987 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "EGTX.ST": {"short_name": "Egetis Therapeutics AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "EI9.F": {"short_name": "ELOS MED.AB B(FRIA)SK6,25", "long_name": "Elos Medtech AB (publ)", "summary": "Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. The company operates in three segments: Dental, Orthopedics, and Life Science. Its products include implants, screws, plates, instruments, drills, pins and wires, prosthetics, digital dentistry workflow products, disposable plastics, HPLC fittings, and other medical plastic parts, as well as original equipment manufacturing products. The company also provides design and development, regulatory, prototyping, testing, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was founded in 1923 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "EJXB.F": {"short_name": "ELEKTA AB  B  SK 2", "long_name": "Elekta AB (publ)", "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "EKTA-B.ST": {"short_name": "Elekta AB ser. B", "long_name": "Elekta AB (publ)", "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "EKTAF": {"short_name": "ELEKTA", "long_name": "Elekta AB (publ)", "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "EKTAY": {"short_name": "ELEKTA", "long_name": "Elekta AB (publ)", "summary": "Elekta AB (publ), a medical technology company, provides clinical solutions for cancer and brain disorders worldwide. The company offers radiotherapy treatment systems, such as Versa HD, a dose delivery accuracy system; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "ELOS-B.ST": {"short_name": "Elos Medtech AB ser. B", "long_name": "Elos Medtech AB (publ)", "summary": "Elos Medtech AB (publ) develops and manufactures medical devices and components for the medical technology industry. The company operates in three segments: Dental, Orthopedics, and Life Science. Its products include implants, screws, plates, instruments, drills, pins and wires, prosthetics, digital dentistry workflow products, disposable plastics, HPLC fittings, and other medical plastic parts, as well as original equipment manufacturing products. The company also provides design and development, regulatory, prototyping, testing, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was founded in 1923 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "EN9.F": {"short_name": "ENZYMATICA AB", "long_name": "Enzymatica AB", "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of common cold. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; Cortagrip name in Spain; ViruProtect name in Austria and Belgium; and ColdGuard name in South Africa. The company also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was founded in 2007 and is based in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "ENZY.ST": {"short_name": "Enzymatica AB", "long_name": "Enzymatica AB", "summary": "Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Its product includes ColdZyme mouth spray, which prevents cold and reduces the duration of common cold. The company also provides ColdZyme mouth spray under the PreCold name in Iceland; Cortagrip name in Spain; ViruProtect name in Austria and Belgium; and ColdGuard name in South Africa. The company also offers STADAProtect, a mouth spray to protect and care oral cavity, as well as enzyme formulations. Enzymatica AB was founded in 2007 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "EPIS-B.ST": {"short_name": "Episurf Medical AB B", "long_name": "Episurf Medical AB (publ)", "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, and the United Kingdom. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for treating elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Epiguide MOS, a surgical drill guide, which is designed for use in mosaicplasty surgery for treatment of cartilage and deep underlying bone defects in the knee joint. In addition, the company offers \u00c2\u00b5iFidelity system for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was founded in 2008 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "EPSFF": {"short_name": "EPISURF MEDICAL AB", "long_name": "Episurf Medical AB (publ)", "summary": "Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in the Nordic countries, Benelux, Germany, and the United Kingdom. The company offers Episealer Condyle Solo for the treatment of localized cartilage and underlying bone defects on the femoral condyles of the knee joint; Episealer Trochlea Solo to treat localized cartilage and underlying bone defects in the area behind the patella; and Episealer Femoral Twin for treating elongated localized cartilage and underlying bone defects on the femoral condyles and in the trochlea area of the knee joint. It also provides Epiguide MOS, a surgical drill guide, which is designed for use in mosaicplasty surgery for treatment of cartilage and deep underlying bone defects in the knee joint. In addition, the company offers \u00c2\u00b5iFidelity system for damage assessment, surgical pre-planning, and patient customization of implants and related surgical instruments; and Epioscopy, a damage assessment tool. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was founded in 2008 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "ERMA.ST": {"short_name": "Enorama Pharma AB", "long_name": "Enorama Pharma AB (publ)", "summary": "Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "FEEL.ST": {"short_name": "Feelgood Svenska AB", "long_name": "Feelgood Svenska AB (publ)", "summary": "Feelgood Svenska AB (publ) provides a range of health services to businesses, organizations, and private individuals in Sweden. The company offers health, exercise, and physiotherapy services. Feelgood Svenska AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Healthcare Plans", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "FGS.SG": {"short_name": "Feelgood Svenska AB Namn-Aktier", "long_name": "Feelgood Svenska AB (publ)", "summary": "Feelgood Svenska AB (publ) provides a range of health services to businesses, organizations, and private individuals in Sweden. The company offers health, exercise, and physiotherapy services. Feelgood Svenska AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Healthcare Plans", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "FLUI.ST": {"short_name": "Fluicell AB", "long_name": "Fluicell AB (publ)", "summary": "Fluicell AB (publ) provides single-cell discovery platforms for biomedicine, drug development, and bioprinting applications worldwide. The company offers BioPen PRIME and BioPen FLEX microfluidic systems for maintaining localized solution delivery in single-cell experiments, as well as enabling control of the chemical environment around single intact cells in tissue or cell cultures; and Dynaflow Resolve system, a secondary ion channel screening platform, which allows for recording of various ion channel current in patch-clamp recording configuration. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "FRISQ.ST": {"short_name": "FRISQ Holding AB", "long_name": "FRISQ Holding AB (publ)", "summary": "FRISQ Holding AB (publ) develops digital solutions for interactive communication between various actors in the care chain. The company offers FRISQ Care, an application that enables the digitalization of care processes and makes them available for patients and care teams. Its application provides the patient with information about its care plan, medication, and care history accessed directly on its mobile device. The company is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "GABA.ST": {"short_name": "Gabather AB", "long_name": "Gabather AB (publ)", "summary": "Gabather AB (publ) develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer's disease. The company was founded in 2014 and is based in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "GENO.ST": {"short_name": "Genovis AB", "long_name": "Genovis AB (publ.)", "summary": "Genovis AB (publ.) develops, produces, and sells tools for developing drugs for customers in the medical device and pharmaceutical industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1 at one specific site above the hinge and generating intact Fab and Fc fragments; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for producing a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge. In addition, the company offers GingisREX, a cysteine protease that specifically digests peptide bonds C-terminally to arginine residues, including arginine linked to proline; and IgGZERO (EndoS), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes N-linked glycans in the Fc-region of native IgG. Further, it provides IgGZERO LE, an endoglycosidase acting on complex type N-glycans from Streptococcus pyogenes; deGlycIT, an IgGZERO (EndoS) enzyme for agarose beads for deglycosylation of Fc-glycans; GlycINATOR an endoglycosidase from Streptococcus pyogenes that hydrolyzes the all glycoforms structure; and GlycINATOR (EndoS2), an endoglycosidase from Streptococcus pyogenes that specifically hydrolyzes glycans at the Fc glycosylation site of IgG. Additionally, the company offers GlyCLICK, a site-specific conjugation technology used for IgG on enzymatic remodeling of the Fc glycans and click chemistry; SialEXO, a sialidase product for the removal and analysis of sialic acids; enzymes for O-glycans; and antibody fragmentation services, as well as operates online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Sweden, Europe, North America, and Asia. The company was founded in 1999 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "GETI-B.ST": {"short_name": "Getinge AB ser. B", "long_name": "Getinge AB", "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; critical care ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, Asia, and Pacific regions. The company has a partnership with Verb Surgical Inc. to develop robotic surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "GHP.ST": {"short_name": "GHP Specialty Care AB", "long_name": "GHP Specialty Care AB (publ)", "summary": "GHP Specialty Care AB (publ) provides healthcare services in the Nordic region and internationally. The company operates specialist clinics that offer services in various areas, including orthopaedics, spine surgery/spine care, obesity surgery and diabetes care, gastroenterology, urology, general surgery, arrhythmia, sports medicine, neurology, skin, and specialist dentistry. It operates 22 specialty care clinics in the Nordic Region. The company was formerly known as Global Health Partner AB (publ) and changed its name to GHP Specialty Care AB (publ) in May 2015. GHP Specialty Care AB (publ) was founded in 2006 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "GNGBF": {"short_name": "GETINGE AB", "long_name": "Getinge AB", "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; critical care ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, Asia, and Pacific regions. The company has a partnership with Verb Surgical Inc. to develop robotic surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Gothenburg"}, "GNGBY": {"short_name": "GETINGE AB", "long_name": "Getinge AB", "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; critical care ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, Asia, and Pacific regions. The company has a partnership with Verb Surgical Inc. to develop robotic surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Gothenburg"}, "GPXMED.ST": {"short_name": "GPX Medical AB", "long_name": "GPX Medical AB (publ)", "summary": "GPX Medical AB operates as a medical technology company. It offers neonatal intensive care with NEOLA, a medical device that offer continuous lung monitoring and real-time alerts of life-threatening complications using technology that measures lung volume changes and oxygen gas concentration. NEOLA provide intensive care and healthier lives for preterm born infants. The company was founded in 2016 and headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "GTN.F": {"short_name": "GETINGE AB  B FR. SK-,50", "long_name": "Getinge AB", "summary": "Getinge AB provides products and solutions for operating rooms, intensive-care units, sterilization departments, and life science companies and institutions. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, and logistic automation solutions; practice-oriented monitoring systems and disposables, vascular and cardiothoracic surgery solutions, anesthesia machines, beating heart surgery solutions, ceiling supply units, connected solutions, and indicators, as well as washer-disinfectors, consumables, and IT-solutions. The company also provides endovascular products; chest drain products; endoscope reprocessing; endoscopic vessel harvesting systems; critical care ventilators; extracorporeal life support or extracorporeal membrane oxygenation products; intra-aortic balloon counter pulsation therapies; operating lights; and modular room systems. In addition, it offers operating tables and accessories; operating room (OR) furniture; OR integration systems; OR management solutions; loading and distribution trolleys; patient flow management and transport solutions; sealing equipment; sterile supply management and traceability solutions; surgical perfusion components; surgical assist systems; and trays and baskets, as well as inspection and packaging and after sales consulting services. Further, the company provides professional financial advisory services to hospitals and medical facilities; and education and training services. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, Asia, and Pacific regions. The company has a partnership with Verb Surgical Inc. to develop robotic surgery solutions. Getinge AB was founded in 1904 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "HANDI.ST": {"short_name": "Handicare Group AB", "long_name": "Handicare Group AB (publ)", "summary": "Handicare Group AB (publ) provides mobility products and solutions for physically challenged or elderly people in North America, Asia, and Europe. The company manufactures and sells curved and straight stair lifts, transfer products, lifting and repositioning aids, vehicle accessibility products, and medical equipment and consumables, as well as offers maintenance and installation services. It serves hospitals, long-term care facilities, home care, and private individuals through dealers, and government and local authorities. The company was founded in 1986 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "HEMC.ST": {"short_name": "Hemcheck Sweden AB", "long_name": "Hemcheck Sweden AB (publ)", "summary": "Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergency departments in the European Union and the United States. The company was founded in 2010 and is based in Karlstad, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Karlstad"}, "HNSA.ST": {"short_name": "Hansa Biopharma AB", "long_name": "Hansa Biopharma AB (publ)", "summary": "Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barr\u00c3\u00a9 syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company also has licensing agreement with Axis-Shield Diagnostics Limited for Heparin Binding Protein (HBP)-assay, a method that predicts severe sepsis in emergency clinics. Hansa Biopharma AB (publ) is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IBT-B.ST": {"short_name": "Infant Bacterial Therapeutics A", "long_name": "Infant Bacterial Therapeutics AB (publ)", "summary": "Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting infants. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ICO.ST": {"short_name": "Iconovo AB", "long_name": "Iconovo AB (publ)", "summary": "Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a reservoir-based dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a unit dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler, as well as provides customized inhalation solutions. It serves generic companies. The company was founded in 2013 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IDOGEN.ST": {"short_name": "Idogen AB", "long_name": "Idogen AB (publ)", "summary": "Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. Its advanced product candidate is IDO 8, designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII. The company also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection, primarily kidney transplant rejection; and IDO AID for severe and rare autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IMMNOV.ST": {"short_name": "Immunovia AB", "long_name": "Immunovia AB (publ)", "summary": "Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "IRLAB-A.ST": {"short_name": "IRLAB Therapeutics AB ser. A", "long_name": "IRLAB Therapeutics AB (publ)", "summary": "IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam, a dopamine D3 receptor antagonist that has completed Phase IIa clinical trial for the treatment of dyskinesia; IRL752 that has completed Phase IIa clinical trial to treat postural dysfunction; and IRL942 and 1009, a research program for the treatment of neurodegenerative disorders and ageing. It also develops P001, a research project for neurodegenerative disorders and aging; P003, a research project aiming at developing drugs that can substitute levodopa as the treatment of Parkinson's disease; and IRL448/IRL555, a follow\u00c2\u0096up to Parkinson's disease program. The company is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "IRRAS.ST": {"short_name": "IRRAS AB", "long_name": "IRRAS AB (publ)", "summary": "IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to improve the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma. The company also provides Hummingbird ICP monitoring system comprising Hummingbird ICP Control Module (HICP200) and the related catheters, which include SynergyDuo Ventricular Catheter (H610), and Parenchymal Catheter (H110); and Hummingbird neuromonitoring products to manage patients suffering from conditions that cause an elevated intracranial pressure, including traumatic brain injury, subarachnoid hemorrhage, and strokes. The company markets and sells its products to hospitals through its direct sales force and a network of distribution partners. IRRAS AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ISOFOL.ST": {"short_name": "Isofol Medical AB", "long_name": "Isofol Medical AB (publ)", "summary": "Isofol Medical AB (publ), a biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops Arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was founded in 2008 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "ISR.ST": {"short_name": "ISR Immune System Regulation Ho", "long_name": "ISR Immune System Regulation Holding AB (publ)", "summary": "ISR Immune System Regulation Holding AB (publ) researches and develops drugs for the treatment of viral infections in Sweden. The company's product candidates include ISR048 that has completed Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in the development stage to treat HIV. It is also developing a second line of chemical entities, including ISR050 that has immunostimulatory properties. The company is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "ITECH.ST": {"short_name": "I-Tech AB", "long_name": "I-Tech AB", "summary": "I-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. It serves marine coatings manufacturers. The company was founded in 2000 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "IVACC.ST": {"short_name": "Intervacc AB", "long_name": "Intervacc AB (publ)", "summary": "Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company is based in H\u00c3\u00a4gersten, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "H\u00c3\u00a4gersten"}, "IZAFE-B.ST": {"short_name": "iZafe Group AB ser. B", "long_name": "iZafe Group AB (publ)", "summary": "iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug dispenser for homecare that reminds patients when to take medication and triggers an alarm if a patient fails to do so. It also provides MediKoll, an app that offers patients information about side effects, reactions, and allergies related to various types of medication. The company offers its products for the pharmaceutical, hospital and care home, and pharmacy and private healthcare markets. The company was formerly known as MediR\u00c3\u00a4tt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was founded in 2008 and is based in Liding\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Liding\u00c3\u00b6"}, "KAN.ST": {"short_name": "Kancera AB", "long_name": "Kancera AB (publ)", "summary": "Kancera AB (Publ), a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. It develops drugs for the treatment of inflammation and cancer. The company's drug development projects include ROR inhibitors for the treatment of leukemia and solid tumors; PFKFB3 inhibitors for reducing cancer's energy supply and inhibiting DNA repair; HDAC6 for the treatment of nerve inflammation and pain; and KAND567 and KAND145 that block the receptor for fractalkine and specific parts of the immune system, as well as for the treatment of heart injury after myocardial infarction. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "KARO.ST": {"short_name": "Karo Pharma AB", "long_name": "Karo Pharma AB (publ)", "summary": "Karo Pharma AB (publ) develops and markets prescription drugs, over-the-counter products, medical devices, and hospital supply products for pharmacies and the health care sectors in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. Its prescription drugs include Mollipect and TheoDur for respiratory diseases; Probecid for gout; Burinex, Centyl K, Kaleorid, Suscard, Nitroglycerin BioPhausia, and Digoxin BioPhausia for cardiovascular diseases; Laxabon and Egazil for gastro/intestinal diseases; Condyline, Synalar, Mildison, Fonx, and Conotrane for dermatology diseases; Paraflex for musculoskeletal diseases; Dolerin, Citodon, Morfin Special, Paralgin forte, and Trampalgin for pain; Ibux, Paracet, and Viruseptin for pain, cough, and cold; Bronkyl and Bronkyl forte for cold/flu diseases; Selexid for antibiotics; Solvezink for zinc deficiency; Lithionit for CNS/psychiatry diseases; Metformin for diabetes; and Zonat for insomnia. The company also offers BabySlide, a medical device; Dosett, a solution for the storage of medicine; Mabs compression socks; and Swereco, which offers a product assortment of ergonomic products for people with disabilities. In addition, it provides skin care products, such as CCS gel, Decubal, Fungobase, Fungoral, Karbasal, KidsClin, Locobase, Oliva, PoxClin, and Propyless; foot care products, including CCS, Cortimyk, Footner, Nailner, and Wortie; and intimate care products comprising HemoClin, Multi-Gyn, Asan, Multi-Mam, and Pevaryl. Further, the company offers nutritional and wellness products, such as All\u00c3\u00a9vo, Bamse, Betavivo, Clinomyn, DAX, Dosett, Flux, Dailycare/Lactocare, and Indy Beauty. It sells its products to retailers, pharmacies, and hospitals, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was founded in 1987 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "KDEV.ST": {"short_name": "Karolinska Development AB ser.B", "long_name": "Karolinska Development AB (publ)", "summary": "Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "KLAR.ST": {"short_name": "Klaria Pharma Holding AB", "long_name": "Klaria Pharma Holding AB (publ.)", "summary": "Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "KONT.ST": {"short_name": "Kontigo Care AB", "long_name": "Kontigo Care AB (publ)", "summary": "Kontigo Care AB (publ) provides health care solutions for addiction treatment in Sweden. It offers Previct Alcohol, a digital medical device for the drug rehabilitation; and Previct Gambling, a digital tool for the treatment and prevention of work at the gaming addiction. Kontigo Care AB (publ) was founded in 2013 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "L7R.F": {"short_name": "LIPIDOR AB", "long_name": "Lipidor AB (publ)", "summary": "Lipidor AB (publ), a pharmaceutical development company, develops drugs for the treatment of skin diseases. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin infections, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, acne treatment, and wart treatment. Lipidor AB (publ) has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was founded in 2009 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "LC8A.F": {"short_name": "CALLIDITAS THERAP. AD 1/2", "long_name": "Calliditas Therapeutics AB (publ)", "summary": "Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "LIDDS.ST": {"short_name": "LIDDS AB", "long_name": "LIDDS AB (publ)", "summary": "LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an antibody-based immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. The company is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "LIPI.ST": {"short_name": "Lipidor AB", "long_name": "Lipidor AB (publ)", "summary": "Lipidor AB (publ), a pharmaceutical development company, develops drugs for the treatment of skin diseases. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin infections, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, acne treatment, and wart treatment. Lipidor AB (publ) has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was founded in 2009 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "LUR.F": {"short_name": "LUXBRIGHT AB", "long_name": "Luxbright AB (publ)", "summary": "Luxbright AB, a technology company, develops and commercializes X-ray tubes, generators, and other X-ray systems to system suppliers. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "LXB.ST": {"short_name": "Luxbright AB", "long_name": "Luxbright AB (publ)", "summary": "Luxbright AB, a technology company, develops and commercializes X-ray tubes, generators, and other X-ray systems to system suppliers. The company was founded in 2012 and is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "M02.SG": {"short_name": "IZafe Group AB Namn-Aktier B o.", "long_name": "iZafe Group AB (publ)", "summary": "iZafe Group AB (publ), a medical technology company, researches, develops, and markets medical products for medication and drug management in Sweden and internationally. The company offers Dosell, a drug dispenser for homecare that reminds patients when to take medication and triggers an alarm if a patient fails to do so. It also provides MediKoll, an app that offers patients information about side effects, reactions, and allergies related to various types of medication. The company offers its products for the pharmaceutical, hospital and care home, and pharmacy and private healthcare markets. The company was formerly known as MediR\u00c3\u00a4tt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was founded in 2008 and is based in Liding\u00c3\u00b6, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Liding\u00c3\u00b6"}, "MAGLE.ST": {"short_name": "Magle Chemoswed Holding AB", "long_name": "Magle Chemoswed Holding AB (publ)", "summary": "Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacture of pharmaceutical products and technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); research, development, and production of products in the areas of wound care and diagnostics, with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical device technology products in the areas of advanced wound care, surgical and diagnostics, drug delivery, which include its marketed technology products comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; and SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company is headquartered in Malm\u00c3\u00b6, Sweden. Magle Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "MB8A.F": {"short_name": "MOBERG PHARMA AB", "long_name": "Moberg Pharma AB (publ)", "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Bromma"}, "MCOV-B.ST": {"short_name": "Medicover AB ser. B", "long_name": "Medicover AB (publ)", "summary": "Medicover AB (publ) provides healthcare and diagnostic services in Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, Sweden, India, and Hungary. The company operates in two divisions, Diagnostic Services and Healthcare Services. Its diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company offers outpatient and inpatient healthcare services, including fertility treatment, dental, elderly care, eye care, and skin and wellness services, as well as fitness and pharmacy solutions. It operates 96 clinical laboratories, 670 blood-drawing points, and 25 clinics in 10 countries; and 120 medical clinics, 21 fertility clinics, 41 dental clinics, and 20 hospitals. The company serves corporate and private customers, and patients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "MCVEF": {"short_name": "MEDICOVER AB", "long_name": "Medicover AB (publ)", "summary": "Medicover AB (publ) provides healthcare and diagnostic services in Germany, Romania, Ukraine, Poland, Belarus, Moldova, Serbia, Turkey, Georgia, Bulgaria, Sweden, India, and Hungary. The company operates in two divisions, Diagnostic Services and Healthcare Services. Its diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology. The company offers outpatient and inpatient healthcare services, including fertility treatment, dental, elderly care, eye care, and skin and wellness services, as well as fitness and pharmacy solutions. It operates 96 clinical laboratories, 670 blood-drawing points, and 25 clinics in 10 countries; and 120 medical clinics, 21 fertility clinics, 41 dental clinics, and 20 hospitals. The company serves corporate and private customers, and patients. Medicover AB (publ) was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "MN2.F": {"short_name": "MENTICE AB  SK -,20", "long_name": "Mentice AB (publ)", "summary": "Mentice AB (publ) provides endovascular simulation solutions to the hospitals and training centers, and medical device manufacturers worldwide. The company operates through three segments: Medical Device Industry, Teaching Entities, and Healthcare systems. The company provides software modules in the areas of acute ischemic stroke intervention, aortic valve implantation, atrial septal defect and patent foramen ovale occlusion, below-the-knee intervention, cardiac rhythm management, carotid intervention, coronary angiography, coronary PRO, endovascular aortic repair, Iliac/SFA intervention, left atrial appendage occlusion, neurovascular intervention, peripheral angiography, prostatic artery embolization, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, and vascular trauma management. It offers flight simulations to physicians and clinical teams. The company's products are used to educate, train, and improve the practitioner's skills in different types of interventions and new clinical instruments. The company was founded in 1999 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "MNTC.ST": {"short_name": "Mentice AB", "long_name": "Mentice AB (publ)", "summary": "Mentice AB (publ) provides endovascular simulation solutions to the hospitals and training centers, and medical device manufacturers worldwide. The company operates through three segments: Medical Device Industry, Teaching Entities, and Healthcare systems. The company provides software modules in the areas of acute ischemic stroke intervention, aortic valve implantation, atrial septal defect and patent foramen ovale occlusion, below-the-knee intervention, cardiac rhythm management, carotid intervention, coronary angiography, coronary PRO, endovascular aortic repair, Iliac/SFA intervention, left atrial appendage occlusion, neurovascular intervention, peripheral angiography, prostatic artery embolization, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, and vascular trauma management. It offers flight simulations to physicians and clinical teams. The company's products are used to educate, train, and improve the practitioner's skills in different types of interventions and new clinical instruments. The company was founded in 1999 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "MOB.ST": {"short_name": "Moberg Pharma AB", "long_name": "Moberg Pharma AB (publ)", "summary": "Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Bromma"}, "MVIR-B.ST": {"short_name": "Medivir AB ser. B", "long_name": "Medivir AB (publ)", "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "MVR.F": {"short_name": "MEDIVIR AB B  SK 10", "long_name": "Medivir AB (publ)", "summary": "Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The company markets Xerclear for use in the treatment of labial herpes under the Zoviduo name. It develops Remetinostat, which has completed phase II clinical trial for treating cutaneous T-cell lymphoma, as well as in phase II clinical trial for treating basal cell carcinoma; and Birinapant that is in phase II clinical trial for treating colorectal cancer. The company also develops MIV-818, which is in phase Ia clinical trial for treating liver cancer; MIV-828, a candidate drug for treating blood cancer; MIV-711, which is in phase II clinical trial for treating osteoarthritis; and MIV-802, a nucleotide-based drug candidate for treating hepatitis C infections. It sells its products in Sweden, the Nordic region, Europe, the United States, and the rest of the world. The company has a research collaboration with the Drug Discovery and Development Platform and SciLifeLab for the discovery of antivirals for SARS CoV-2. Medivir AB (publ) was founded in 1988 and is based in Huddinge, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Huddinge"}, "NANEXA.ST": {"short_name": "Nanexa AB", "long_name": "Nanexa AB", "summary": "Nanexa AB engages in the development of drug delivery systems worldwide. It operates PharmaShell, a nanobased drug delivery platform that is based on a coating technique called atomic layer deposition. The company offers a gas barrier that prevents xenon gas from penetrating detectors used in this assay equipment; and a coating system for medical polymeric products that protects against fungal spreads, such as the common fungal genus Candida. Nanexa AB was founded in 2007 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "NEVPF": {"short_name": "ABLIVA AB", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Lund"}, "NTP.F": {"short_name": "ABLIVA AB AK", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}, "NXTCL.ST": {"short_name": "NextCell Pharma AB", "long_name": "NextCell Pharma AB", "summary": "NextCell Pharma AB operates as a tissue establishment and primary biobank in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases, as well as for use in kidney transplants. It also provides a service under the Cellaviva brand name, which is a stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue. The company has a partnership with Bonzun Health Information AB. NextCell Pharma AB was founded in 2014 and is based in Huddinge, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Huddinge"}, "OASM.ST": {"short_name": "Oasmia Pharmaceutical AB", "long_name": "Oasmia Pharmaceutical AB (publ)", "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "OASMY": {"short_name": "OASMIA PHARMACEUTICAL AB SPON A", "long_name": "Oasmia Pharmaceutical AB (publ)", "summary": "Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer. It also provides Doxophos, a patented formulation of cytostatic doxorubicin in combination with XR-17 Doxorubicin for the treatment of various forms of cancers, including blood, skeleton, breast, prostate, and lungs; and KB9520, a substance that is in pre-clinical stage to reduce the side effects of cytostatics treatment. In addition, the company's animal health product portfolio includes Paccal Vet, a patented formulation of paclitaxel for the treatment of mammary carcinoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Additionally, its technology platform portfolio comprises XR-19, an internal technology, which is under assessment process for a dual encapsulation technology; and XR-17, a proprietary solubility-enhancing technology platform in oncology and other therapeutic areas. Oasmia Pharmaceutical AB (publ) was founded in 1988 and is headquartered in Uppsala, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Uppsala"}, "ONCO.ST": {"short_name": "Oncopeptides AB", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "OND.F": {"short_name": "ONCOPEPTIDES AB O.N.", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "ONPPF": {"short_name": "ONCOPEPTIDES AB", "long_name": "Oncopeptides AB (publ)", "summary": "Oncopeptides AB (publ), a pharmaceutical company, develops pharmaceuticals drugs for the treatment of cancer. Its lead product candidate is melflufen, a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "ORTI-A.ST": {"short_name": "Ortivus AB ser. A", "long_name": "Ortivus AB (publ)", "summary": "Ortivus AB (publ) develops and supplies mobile monitoring and communication solutions for the medical care industry in Sweden and internationally. It offers MobiMed, a modular software for electronic patient records and real-time monitoring of vital parameters; M531, a portable measurement unit for various parameters, such as ECG, saturation, and real-time blood pressure that integrates with the MobiMed software; and PG1-1, a patient unit adapted for the MobiMed software. The company also provides PM1-1, a robust patient unit designed for use with the MobiMed software; CS-1, a support system for M531 measuring unit, patient unit PM1-1, and associated cables and sensors; and CoroNet, a mobile monitoring solution for staff to access monitoring information of patients. In addition, it offers healthcare IT consulting services for planning, design, implementation, and integration projects; and support, implementation, and training services. Ortivus AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Danderyd"}, "ORTI-B.ST": {"short_name": "Ortivus AB ser. B", "long_name": "Ortivus AB (publ)", "summary": "Ortivus AB (publ) develops and supplies mobile monitoring and communication solutions for the medical care industry in Sweden and internationally. It offers MobiMed, a modular software for electronic patient records and real-time monitoring of vital parameters; M531, a portable measurement unit for various parameters, such as ECG, saturation, and real-time blood pressure that integrates with the MobiMed software; and PG1-1, a patient unit adapted for the MobiMed software. The company also provides PM1-1, a robust patient unit designed for use with the MobiMed software; CS-1, a support system for M531 measuring unit, patient unit PM1-1, and associated cables and sensors; and CoroNet, a mobile monitoring solution for staff to access monitoring information of patients. In addition, it offers healthcare IT consulting services for planning, design, implementation, and integration projects; and support, implementation, and training services. Ortivus AB (publ) was founded in 1985 and is headquartered in Danderyd, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Danderyd"}, "ORX.ST": {"short_name": "Orexo AB", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "ORXOY": {"short_name": "OREXO AB", "long_name": "Orexo AB (publ)", "summary": "Orexo AB (publ), a specialty pharmaceutical company, and its subsidiaries develop and commercialize pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. The company's digital therapies comprise OXD01 for opioid use disorder and OXD02/vorvida for alcohol use disorder. Orexo AB (publ) has partnerships with Lyfebulb to recover from alcohol and opioid use disorders; and GoGoMeds to provide digital therapies deprexis and vorvida available for the treatment of depression and management of problematic alcohol misuse. The company was founded in 1995 and is headquartered in Uppsala, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Uppsala"}, "OSSD.ST": {"short_name": "OssDsign AB", "long_name": "OssDsign AB (publ)", "summary": "OssDsign AB (publ), a medtech company, designs, manufactures, and markets implants for healing of bone defects in Sweden and internationally. Its products include OSSDSIGN cranial, an implant solution for cranioplasty patients, as well as related accessories; OSSDSIGN facial to treat patients with complex facial skeletal defects; and OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage. The company was founded in 2011 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "P0F.F": {"short_name": "EGETIS THERAPEUTICS AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "P0F.SG": {"short_name": "EGETIS THERAPEUTICS AB", "long_name": "Egetis Therapeutics AB (publ)", "summary": "Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. It engages in developing PledOx, which is in Phase III clinical trial to protect patients from nerve damage caused by chemotherapy without reducing its anticancer effects; Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling; and Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. The company was founded in 2006 and is headquartered in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "PAPI.ST": {"short_name": "Papilly AB", "long_name": "Papilly AB (publ)", "summary": "Papilly AB (publ) operates as a healthcare company that provides Internet-based health services in Sweden. The company offers solutions for stress-related disorders. It also provides support services to the therapists who work with stress, cardiovascular disease, anxiety, relationship problems, etc. The company was formerly known as Stresscompany AB (publ) and changed its name to Papilly AB (publ) in May 2015. Papilly AB (publ) is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "PAX.ST": {"short_name": "Paxman AB", "long_name": "Paxman AB (publ)", "summary": "Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. It serves various cancer centers and hospitals. Paxman AB (Publ) has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. The company was founded in 1996 and is headquartered in Karlshamn, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Karlshamn"}, "PHLOG-B.ST": {"short_name": "Pharmacolog i Uppsala AB ser. B", "long_name": "Pharmacolog i Uppsala AB (publ)", "summary": "Pharmacolog i Uppsala AB (publ) develops systems and solutions for use of intravenous drugs in Sweden. The company offers DrugLog, a solution for reducing errors in the drug administration process; WasteLog, an integrated system to monitor and safeguard discarded narcotics from surgical procedures; and PerpLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of end result. The company was founded in 2007 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "PLUN.ST": {"short_name": "ProstaLund AB", "long_name": "ProstaLund AB (publ)", "summary": "ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Care Facilities", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "PQX1.F": {"short_name": "BIOTAGE AB  SK 1", "long_name": "Biotage AB", "summary": "Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Uppsala"}, "PROB.ST": {"short_name": "Probi AB", "long_name": "Probi AB (publ)", "summary": "Probi AB (publ), a bioengineering company, researches, develops, manufactures, markets, and sells probiotics for food, health, and pharmaceutical companies. The company operates in two segments, Consumer Healthcare and Functional Food. It conducts research primarily in the fields of gut health, immune system, nutrient absorption, iron absorption, bone health, and stress and recovery. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a development agreement with Cilag GmbH International for the development of probiotic products; and collaboration with \u00c3\u0096rebro University for research into exploration of novel, needle free vaccines. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "PROGEN.ST": {"short_name": "Prostatype Genomics AB", "long_name": "Prostatype Genomics AB (publ)", "summary": "Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype, a gene test for prostate cancer patients. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "PROMO.ST": {"short_name": "Promore Pharma AB", "long_name": "Promore Pharma AB (publ)", "summary": "Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 for the prevention of post-surgical adhesions and scars, as well as for tendon repair surgery in the hand; and LL-37 that is in Phase IIb clinical studies for treating patients with venous leg ulcers. The company is also developing drugs for the prevention of dermal scars and treatment of diabetic foot ulcers. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "PXMBF": {"short_name": "PAXMAN AB", "long_name": "Paxman AB (publ)", "summary": "Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North and South America, Central America, Asia, and Oceania. It serves various cancer centers and hospitals. Paxman AB (Publ) has a research collaboration agreement with National University Hospital, Singapore for the development of portable cooling and compression device. The company was founded in 1996 and is headquartered in Karlshamn, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Karlshamn"}, "QLIFE.ST": {"short_name": "QLife Holding AB", "long_name": "Qlife Holding AB (publ)", "summary": "Qlife Holding AB (publ), a high-tech medical device company, manufactures and sells in-vitro diagnostic analyzers and reagents. It offers Egoo Home System, an integrated platform consisting of a small home device and disposable capsules each of that test for a specific biomarker, as well as a digital infrastructure that shares data with patient journal or hospital platform. The company has a research agreement with Nordsj\u00c3\u00a6llands Hospital to continue the validation of the Egoo Sars-CoV-2 virus test. The company was founded in 2019 and is based in Helsingborg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Helsingborg"}, "QLINEA.ST": {"short_name": "Q-Linea AB", "long_name": "Q-linea AB (publ)", "summary": "Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system for sepsis patients. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was founded in 2008 and is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "QUIA.ST": {"short_name": "QuiaPEG Pharmaceuticals Holding", "long_name": "QuiaPEG Pharmaceuticals Holding AB (publ)", "summary": "QuiaPEG Pharmaceuticals Holding AB (publ), a biotech company, develops biopharmaceutical products for the treatment of metabolic disorders. It develops biopharmaceuticals based on PEGylation technology platform, which is applicable on proteins, peptides, and small molecules or oligonucleotides. The company has strategic collaboration with Cobra Biologics AB for the refinement of biopharmaceutical products. The company was formerly known as Oligovation AB and changed its name to QuiaPEG Pharmaceuticals Holding AB (publ). QuiaPEG Pharmaceuticals Holding AB (publ) was founded in 2012 and is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "RAY-B.ST": {"short_name": "RaySearch Laboratories AB ser. ", "long_name": "RaySearch Laboratories AB (publ)", "summary": "RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, a oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, and data handling and machine learning. In addition, it provides training courses, as well as customer support services. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "RECI-B.ST": {"short_name": "Recipharm AB ser. B", "long_name": "Recipharm AB (publ)", "summary": "Recipharm AB (publ) provides contract development and manufacturing solutions to the pharmaceutical industry in Sweden, Italy, France, India, Spain, Portugal, Germany, and internationally. It operates through three segments: Manufacturing Steriles & Inhalation, Manufacturing Solids and Others, and Development and Technology. The company manufactures liquid vials and ampoules, lyophilisates, and blow-fill-seal products and inhalation; and tablets, capsules, semi-solids, and non-sterile liquids on behalf of pharmaceutical companies. It also provides supplementary services, such as regulatory, supply chain, active life cycle management, and stability studies and analytical method development services, as well as gateway release and testing services. In addition, the company offers pharmaceutical development services based on various technologies, such as drug substance, drug product, and clinical services to pharmaceutical companies in the drug development phase for new pharmaceuticals; and access to a range of proprietary technologies and intellectual property. Further, it supplies medical devices and veterinary products; and solid, semi-solid, liquid, injectable, and ophthalmic products, as well as serialization services. The company serves various pharma, and research and development companies. The company was founded in 1995 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "RLS.ST": {"short_name": "RLS Global AB", "long_name": "RLS Global AB (publ)", "summary": "RLS Global AB (publ), a medical technology company, develops and sells products for the treatment of diseases in wound and dental care in Sweden. Its products include ChloraSolv that is used for the treatment of chronic foot and leg ulcers for diabetic patients; PeriSolv for the treatment of periodontitis, peri-implant mucositi, and peri-implantitis; and CariSolv, a gel used for treating caries. The company was founded in 1996 and is based in M\u00c3\u00b6lndal, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "M\u00c3\u00b6lndal"}, "RSLBF": {"short_name": "RAYSEARCH LABORATORIES AB", "long_name": "RaySearch Laboratories AB (publ)", "summary": "RaySearch Laboratories AB (publ) develops software solutions for cancer treatment in Sweden and internationally. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, reduce OAR dose, robustness, the physician's toolbox, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomo therapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, a oncology information system for the treatment of cancer comprising oncology treatment activities, including digital oncology workflows, rule-based scheduling, state-of-the-art software platform, enterprise-wide integration, adaptive therapy, and data handling and machine learning. In addition, it provides training courses, as well as customer support services. The company was founded in 2000 and is headquartered in Stockholm, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Stockholm"}, "SCIB.ST": {"short_name": "Scibase Holding AB", "long_name": "SciBase Holding AB (publ)", "summary": "SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions.in Europe and internationally. The company offers Nevisense, a point-of-care detection device for non-visual detection of malignant melanoma. It serves public hospitals and private dermatology clinics. The company has a collaboration agreement with Swiss Institute of Allergy and Asthma Research. The company was founded in 1998 and is headquartered in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "SDOS.ST": {"short_name": "ScandiDos AB", "long_name": "ScandiDos AB (publ)", "summary": "ScandiDos AB (publ) provides measurement systems and software designed for the QA and validation requirements of the new treatments implemented in clinics worldwide. The company offers Delta4 Family solution for pre treatment and at treatment dose verification covering various treatment technologies, such as VMAT, IMRT, SBRT, 4D-RT, and TomoTherapy; Delta4 Discover, a transmission detector that provides confidence and patient safety based on real time measurements; and Delta4 Phantom+, a system that offers accurate and verification of IMRT, VMAT, and TomoTherapy plans. It also provides HexaMotion, a motion management solution; Delta4DVH Anatomy, a software that verifies and analyzes the dose delivered in the patient anatomy; Delta4 Machine QA, a software to perform QA with respect to rotation, start-up behavior, and dynamic beam modulation; and Delta4 Trolley, an ergonomic solution. The company is headquartered in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "SECARE.ST": {"short_name": "Swedencare AB", "long_name": "Swedencare AB (publ)", "summary": "Swedencare AB (publ), together with its subsidiaries, develops, manufactures, distributes, and sells healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff Powder Cat; ProDen PlaqueOff dental bones for dogs; and ProDen PlaqueOff Mini Dental Care Bones, a chewy bone for smaller dogs. The company also provides dietary supplements for cat, dog, and horse under the NutriScience brand, such as Stomax, which enhance digestion; ArthriAid Omega HA and Glucosamine for joints mobility; RevitalAid, a multivitamin supplement; SeniorAid for joint mobility, brain function, immune systems, and nutritional support; KalmAid, which helps to calm anxious and troubled pets; and OmegaAid used for treatment of skin and fur diseases. In addition, it develops and manufactures equine supplements. Further, the company provides ProDen PlaqueOff teeth and gums, a natural food supplement to enhance dental hygiene and prevent tartar buildup for human. It distributes its products through pharmacies, veterinary clinics, pet shops, wholesalers, and online. Swedencare AB (publ) is headquartered in Malm\u00c3\u00b6, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Malm\u00c3\u00b6"}, "SECT-B.ST": {"short_name": "SECTRA AB ser B", "long_name": "Sectra AB (publ)", "summary": "Sectra AB (publ) provides IT systems for managing medical images and patient information related to diagnostic imaging. The company's Imaging IT Solutions segment develops and sells medical IT systems and services for managing, archiving, and presenting various types of medical images and patient information, as well as for operational follow-up and radiation dose monitoring; maintenance services in the form of support and system monitoring; and consulting services related to integration, system design, data migration, and business development. Its Secure Communications segment develops and sells products and services for secure voice and data communications, and protection of society's sensitive IT infrastructure; customized encryption systems and products; and critical infrastructure, which offers security and threat analyses and system monitoring services for control systems in society's critical operations. The company's Business Innovation segment develops and sells IT systems for planning and monitoring orthopedic surgery; and products for medical education and research projects. It serves public and private healthcare providers comprising hospitals, and hospital and private clinic chains; and government agencies and defense departments. Sectra AB (publ) sells its products through its sales organizations and distribution partners in Africa, Europe, the Middle East, North America, Oceania, Southeast Asia, and Japan. The company was founded in 1978 and is headquartered in Link\u00c3\u00b6ping, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Link\u00c3\u00b6ping"}, "SEDANA.ST": {"short_name": "Sedana Medical AB", "long_name": "Sedana Medical AB (publ)", "summary": "Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb-S, a filter containing activated carbon for the removal of waste anaesthetic gases; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb and FlurAbsorb-S mount to hold the filter during scavenging of anesthetic gas. It also provides isoflurane/sevoflurane and Sevorane QuickFil filling adaptors; gas sampling lines to prevent anaesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anaesthetic gas measuring line and the water trap of the gas monitor. In addition, the company develops IsoConDa, a therapy for inhalation sedation in intensive care. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Instruments & Supplies", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Danderyd"}, "SENZA.ST": {"short_name": "SenzaGen AB", "long_name": "SenzaGen AB", "summary": "SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "SEZI.ST": {"short_name": "Senzime AB", "long_name": "Senzime AB (publ)", "summary": "Senzime AB (publ) develps and markets patient monitoring systems to monitor patients under anesthesia in Europe and the United States. The company offers TetraGraph, a TOF-monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; CliniSenz Analyzer, which detects early signs of complications; and Onzurf Probe for sampling from the surface of an organ. Senzime AB (publ) was founded in 1999 and is based in Uppsala, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Uppsala"}, "SIMRIS-B.ST": {"short_name": "Simris Alg AB ser. B", "long_name": "Simris Alg AB (publ)", "summary": "Simris Alg AB (publ) manufactures and sells dietary supplements and algae-based foods in Sweden and internationally. It offers Simris Algae Omega-3, a plant-based marine omega-3 EPA and DHA line; and a line of algae-based products, such as finest chlorella, spirulina sprinkles, boosting astaxanthin, flower power algae tea, and sun candy algae tea under the Simris Select brand. The company was founded in 2010 and is headquartered in Hammenh\u00c3\u00b6g, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Hammenh\u00c3\u00b6g"}, "SOBI.ST": {"short_name": "Swedish Orphan Biovitrum AB", "long_name": "Swedish Orphan Biovitrum AB (publ)", "summary": "Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases. The company offers Alprolix for haemophilia B; Doptelet for chemotherapy induced thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. It also develops drug substance for ReFacto AF; BIVV001 for haemophilia A; BIVV0023 for haemophilia B; and Nirsevimab for respiratory syncytial virus. The company operates in Europe, North America, the Middle East, Russia, North Africa, and Asia. It has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "STABL.ST": {"short_name": "Stayble Therapeutics AB", "long_name": "Stayble Therapeutics AB (publ)", "summary": "Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) is based in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "STIL.ST": {"short_name": "Stille AB", "long_name": "Stille AB", "summary": "Stille AB manufactures and sells surgical instruments in Sweden and internationally. The company offers artery and ligature clamps; artery forceps; bone cutters and rongeurs; clamps; curettes, raspatories, elevators, etc.; forceps; micro instruments; needle holder, wire twistings, and holding forceps; osteotomes, chisels, etc.; reactors and skin hooks; scissors; and other products. It also provides operating tables for ERCP / abdominal fluoroscopy, neuro / spine, pain management, urology, and vascular surgeries. The company was founded in 1841 and is headquartered in Torsh\u00c3\u00a4lla, Sweden. Stille AB is a subsidiary of Linc AB.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Torsh\u00c3\u00a4lla"}, "SUS.ST": {"short_name": "Surgical Science Sweden AB", "long_name": "Surgical Science Sweden AB (publ)", "summary": "Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a portable and ready-to-use VR simulator that fills the gap between lo-fi simulators and fully loaded VR systems; LapSim Haptic System, a force feedback technology with the graphics and cognitive instruction that allows navigation on two touch screens; and LapSim Basic Skills module, which offers a portfolio of laparoscopic exercises that range from basic navigation to advanced suturing. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; and Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "SUSRF": {"short_name": "SURGICAL SCIENCE SWEDEN AB", "long_name": "Surgical Science Sweden AB (publ)", "summary": "Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a portable and ready-to-use VR simulator that fills the gap between lo-fi simulators and fully loaded VR systems; LapSim Haptic System, a force feedback technology with the graphics and cognitive instruction that allows navigation on two touch screens; and LapSim Basic Skills module, which offers a portfolio of laparoscopic exercises that range from basic navigation to advanced suturing. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; and Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Health Information Services", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Gothenburg"}, "SZGEF": {"short_name": "SENZAGEN AB", "long_name": "SenzaGen AB", "summary": "SenzaGen AB markets, sells, and performs in vitro genomic allergen rapid detection (GARD) sensitization tests for the screening of pharmaceutical candidates, and safety assessment of chemicals, complex mixtures, and cosmetic ingredients in Sweden and internationally. It offers GARDskin for predicting the ability of chemicals to induce sensitization; GARDpotency, an animal free test to subcategorize sensitizers according to CLP/GHS classifications by monitoring the expression of 50 complementary genomic biomarkers; and GARDair, an in vitro assay for the prediction of chemical respiratory sensitizers. The company also provides GARDskin medical devices. It offers services through distributors, laboratories, and licensed contract research organizations. SenzaGen AB has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. The company was founded in 2010 and is headquartered in Lund, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Lund"}, "TOL.ST": {"short_name": "Toleranzia AB", "long_name": "Toleranzia AB", "summary": "Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "VICO.ST": {"short_name": "Vicore Pharma Holding AB", "long_name": "Vicore Pharma Holding AB (publ)", "summary": "Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), diffuse systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; and license agreement with Nanologica AB (publ). The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "VITR.ST": {"short_name": "Vitrolife AB", "long_name": "Vitrolife AB (publ)", "summary": "Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors; and pH online. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}, "VTFN.F": {"short_name": "VITROLIFE AB  SK 0,2", "long_name": "Vitrolife AB (publ)", "summary": "Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors; and pH online. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Gothenburg"}, "XBRANE.ST": {"short_name": "Xbrane Biopharma AB", "long_name": "Xbrane Biopharma AB (publ)", "summary": "Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and neck, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars and additional biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "XINT.ST": {"short_name": "Xintela AB", "long_name": "Xintela AB (publ)", "summary": "Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing Xintela Assay for Cell Therapy (XACT), an analytical test for cell therapy. It also offers XSTEM-OA, a stem cell-based product for the treatment of osteoarthritis in humans. In addition, the company develops stem cell-based products for animals. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "XSPRAY.ST": {"short_name": "Xspray Pharma AB", "long_name": "Xspray Pharma AB (publ)", "summary": "Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was founded in 2003 and is based in Solna, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Solna"}, "XVIPF": {"short_name": "XVIVO PERFUSION AB", "long_name": "Xvivo Perfusion AB (publ)", "summary": "Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Gothenburg"}, "XVIVO.ST": {"short_name": "Xvivo Perfusion AB", "long_name": "Xvivo Perfusion AB (publ)", "summary": "Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Medical Devices", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Gothenburg"}}